Clinical trials: Aripiprazole, completed
Chronic Motor or Vocal Tic Disorder, Tourette's Disorder
Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder
The purpose of this trial is to demonstrate the efficacy and safety of aripiprazole in children and adolescents aged 6~18 years with chronic tic disorders or Tourette's disorder
- Trial name
- NCT00706589
- Testing
- aripiprazole
- Where
- 6 sites in South Korea
- Volunteers
- 61 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
The purpose of the trial was to evaluate the efficacy, safety, and tolerability of an intramuscular depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia.
- Trial name
- ASPIRE (NCT00705783)
- Testing
- Aripiprazole depot
- Where
- 110 sites in United States, Argentina and 10 more
- Volunteers
- 843 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder
An Open-Label Trial of Aripiprazole in Children and Adolescents With Bipolar Disorder
This is an investigator-initiated study whose primary aim is to determine the effectiveness of aripiprazole (Abilify®) in helping persons with symptoms of mania whose current medications do not completely control those symptoms.
- Trial name
- NCT00221416
- Testing
- Aripiprazole
- Volunteers
- 30 people
- Sponsor
- University of Cincinnati
Schizophrenia
An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia
The purpose of this study is to evaluate the efficacy and safety of extended-release (ER) paliperidone compared to aripiprazole (atypical antipsychotic) in symptomatic (having symptoms) adolescent participants with schizophrenia…
- Trial name
- NCT01009047
- Testing
- Paliperidone extended release (ER), Aripiprazole
- Where
- 41 sites in United States, India and 5 more
- Volunteers
- 228 people
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study to Compare Capillary and Venous Whole Blood and Plasma Concentrations of Five Antipsychotics
The purpose of this study is to compare capillary (the smallest of a body's blood vessels) and venous whole blood and plasma concentrations of 5 antipsychotics after given of a single oral, immediate-release dose to healthy…
- Trial name
- NCT01607762
- Testing
- Aripiprazole, Quetiapine, Olanzapine
- Where
- Belgium
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Schizophenia Disorder, Schizoaffective Disorder
Study Comparing Patients Taking Olanzapine and Patients Taking Aripiprazole on Learning of Vocational Skills
STUDY PURPOSE: To study whether patients who have schizophrenia or schizoaffective disorder and are randomly assigned to switch to aripiprazole prior to participation in a brief vocational skills training (VST) will have improved…
- Trial name
- NCT00223418
- Testing
- aripiprazole
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Schizophrenia
Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia
This study will compare the safety and effectiveness of three different antipsychotic medications, as well as the use of other medications to limit treatment side effects, in adults with schizophrenia.
- Trial name
- COATS (NCT00802100)
- Testing
- Olanzapine, Perphenazine, Aripiprazole
- Where
- 13 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia
A Placebo-Controlled, Cross-Over Trial of Aripiprazole
This study is a ten-week, placebo-controlled, double-blind, cross-over, randomized trial of the novel antipsychotic agent, aripiprazole, added to 20 obese stable olanzapine-treated patients with schizophrenia or schizoaffective…
- Trial name
- NCT00351936
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- North Suffolk Mental Health Association
Metabolic Syndrome X
Identification and Treatment Response Prediction of Antipsychotic-Related Metabolic Syndrome
The investigators developed an easy identification model to identify metabolic syndrome in patients with schizophrenia or schizoaffective disorder who received treatment of clozapine, olanzapine, or risperidone.
- Trial name
- NCT00956189
- Testing
- amisulpride, aripiprazole
- Where
- 3 sites in Taiwan
- Volunteers
- 132 people
- Sponsor
- National Taiwan University Hospital
Diabetes
Acute Impact of Intramuscular (IM) Aripiprazole and Olanzapine on Insulin Resistance in High Risk Prediabetics
Antipsychotic medicines used to treat mental illnesses have been associated with effects on blood sugar control. Laboratory studies have shown that certain medications in particular may alter how insulin works.
- Trial name
- NCT01411930
- Testing
- Intramuscular olanzapine, aripiprazole, Intramuscular aripiprazole, olanzapine
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Veterans Medical Research Foundation
Depressive Disorder
A PET Study in Healthy Volunteers
This will be an open label, non-randomised [11C]PHNO PET study using healthy male volunteers. Each volunteer will undergo 4 [11C]PHNO PET scans to allow for further characterisation of this radioligand and examine the effects of…
- Trial name
- NCT01424449
- Testing
- [11C]PHNO, Aripiprazole
- Where
- United Kingdom
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Schizophrenia
Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome
Introduction: Schizophrenia is a serious mental illness. For majority of patients it is a lifetime condition,characterized by intermittent episodes of hospitalization due to relapse or acute symptom exacerbation.
- Trial name
- NCT01714011
- Testing
- Ziprasidone, Aripiprazole
- Where
- Malaysia
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- University of Malaya
Major Depressive Disorder
Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression
Our target population will have been adequately treated with one of three selective serotonin reuptake inhibitors (SSRIs; escitalopram, citalopram, or sertraline) for at least 8-12 weeks and continue to experience symptoms of…
- Trial name
- NCT00608543
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Texas Southwestern Medical Center
Schizophrenia, Bipolar Disorder
Aripiprazole Open-Label, Safety and Tolerability Study
The purpose of this study is to test the long-term safety and tolerability of aripiprazole in adolescent patients with schizophrenia, and child and adolescent patients with bipolar I disorder, manic or mixed episode.
- Trial name
- APEX 241 (NCT00102518)
- Testing
- Aripiprazole
- Where
- 50 sites in United States
- Volunteers
- 325 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Psychotic Depression
The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression
The purpose of the study is to assess the safety and effectiveness of the combination of aripiprazole (Abilify) and selective serotonin reuptake inhibitors (SSRIs) in subjects with psychotic major depression.
- Trial name
- Abilify (NCT00556140)
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia
Aripiprazole in Adolescents With Schizophrenia
The purpose of this trial is to test the safety and efficacy of aripiprazole in adolescent patients with schizophrenia for a period of at least 6 weeks.
- Trial name
- APEX 239 (NCT00102063)
- Testing
- Aripiprazole tablet, 10 mg, Aripiprazole tablet, 30 mg
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 302 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder
Aripiprazole in Children and Adolescents With Bipolar I Disorder
The purpose of this trial is to test the safety and efficacy of two doses of aripiprazole in child and adolescent patients with bipolar I disorder, manic or mixed episode with or without psychotic features.
- Trial name
- NCT00110461
- Testing
- Aripiprazole
- Where
- 53 sites in United States
- Volunteers
- 296 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
DSM-IV Schizophrenia, Schizoaffective Disorder
Evaluation of the Strategies of Switching Schizophrenia Patients to Aripiprazole From Other Antipsychotic Agents
The purpose of this study is to determine whether moderately ill Asian schizophrenic patients can be switched from their previous antipsychotic medication to aripiprazole with minimal adverse clinical consequences, and elucidate…
- Trial name
- NCT00545467
- Testing
- Aripiprazole
- Where
- Taiwan
- Volunteers
- 79 people
- Sponsor
- National Taiwan University Hospital
Schizophrenia
Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia
The objective of this study is demonstrate efficacy and a dose-response in the treatment of acute exacerbation of schizophrenia in comparison to placebo.
- Trial name
- NCT00580125
- Testing
- PF-00217830, Aripiprazole
- Where
- 26 sites in United States, India and 2 more
- Volunteers
- 164 people
- Sponsor
- Pfizer
Antipsychotics, Cognition
Change in Brain Metabolism and Cognitive Function by Aripiprazole
Dopamine receptor occupancy and brain metabolism were measured using positron emission tomography after the administration of aripiprazole. Working memory performance was also measured using N-back task.
- Conditions
- Antipsychotics, Cognition, Brain Metabolism, Dopamine Receptor Occupancy
- Trial name
- NCT01562808
- Testing
- Aripiprazole
- Where
- South Korea
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital